About: Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients
Creator	Achilli, Felice Gioffré, Sonia Ruggeri, Clarissa Alessandra, Yuri Colombo, Gualtiero
Source	PMC
abstract	Cardiotoxicity is a well-known side effect of doxorubicin (DOX), but the mechanisms leading to this phenomenon are still not completely clear. Prediction of drug-induced dysfunction onset is difficult and is still largely based on detection of cardiac troponin (cTn), a circulating marker of heart damage. In the last years, several investigations focused on the possible involvement of microRNAs (miRNAs) in DOX-induced toxicity in vitro, with contrasting results. Recently, several groups employed animal models to mimic patient’s condition, investigate the biological pathways perturbed by DOX, and identify diagnostic markers of cardiotoxicity. We reviewed the results from several studies investigating cardiac miRNAs expression in rodent models of DOX-treatment. We also discussed the data from two publications indicating the possible use of circulating miRNA as biomarkers of DOX-induced cardiotoxicity. Unfortunately, limited information was derived from these studies, as selection methods of candidate-miRNAs and heterogeneity in cardiotoxicity assessment greatly hampered the novelty and robustness of the findings. Nevertheless, at least one circulating miRNA, miR-1, showed a good potential as early biomarker of drug-mediated cardiac dysfunction onset. The use of animal models to investigate DOX-induced cardiotoxicity surely helps narrowing the gap between basic research and clinical practice. Despite this, several issues, including selection of relevant miRNAs and less-than-optimal assessment of cardiotoxicity, greatly limited the results obtained so far. Nonetheless, the association of patients-based studies with the use of preclinical models may be the key to address the many unanswered questions regarding the pathophysiology and early detection of cardiotoxicity.
has issue date	2017-09-25(xsd:dateTime)
bibo:doi	10.1007/s10741-017-9653-0
bibo:pmid	28944400
has license	cc-by
sha1sum (hex)	778e39cb165c72b4245262781d804c4e1f6da3d7
schema:url	https://doi.org/10.1007/s10741-017-9653-0
resource representing a document's title	Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients
has PubMed Central identifier	PMC5756562
has PubMed identifier	28944400
schema:publication	Heart Fail Rev
resource representing a document's body	covid:778e39cb165c72b4245262781d804c4e1f6da3d7#body_text
is schema:about of	named entity 'CANCER' named entity 'groups' named entity 'miRNAs' named entity 'cardiac' named entity 'studies' named entity 'animal models' named entity 'gap' named entity 'circulating' named entity 'drug-induced' named entity 'patient' named entity 'condition' named entity 'cancer' named entity 'DOXORUBICIN' named entity 'MARKER' named entity 'RODENT' named entity 'REVIEWED' named entity 'BUT' named entity 'INFORMATION' named entity 'KEY' named entity 'IDENTIFY' named entity 'LARGELY' named entity 'INDICATING' named entity 'LESS-THAN' named entity 'CONDITION' named entity 'STUDIES' named entity 'PRECLINICAL MODELS' named entity 'HEART' named entity 'MIMIC' named entity 'POSSIBLE' named entity 'INVESTIGATE' named entity 'FAR' named entity '27S' named entity 'DOXORUBICIN' named entity 'KNOWN' named entity 'CONTRASTING' named entity 'ISSUES' named entity 'HETEROGENEITY' named entity 'RELEVANT' named entity 'DIFFICULT' named entity 'GREATLY' named entity 'TREATMENT' named entity 'MECHANISMS' named entity 'MIRNAS' named entity 'NARROWING' named entity 'PUBLICATIONS' named entity 'EXPRESSION' named entity 'IN VITRO' named entity 'PATHOPHYSIOLOGY' named entity 'BIOMARKER' named entity 'EARLY DETECTION' named entity 'USE OF' named entity 'BIOMARKERS' named entity 'TOXICITY' named entity 'POTENTIAL' named entity 'BASIC RESEARCH' named entity 'ASSOCIATION OF PATIENTS' named entity 'DETECTION' named entity 'CARDIAC DYSFUNCTION' named entity 'YEARS' named entity 'GOOD' named entity 'OBTAINED' named entity 'CARDIAC' named entity 'HELPS' named entity 'INVESTIGATIONS' named entity 'EARLY' named entity 'TO INVESTIGATE' named entity 'CARDIAC TROPONIN' named entity 'FINDINGS' named entity 'IS A' named entity 'THE GAP' covid:arg/778e39cb165c72b4245262781d804c4e1f6da3d7 named entity 'OPTIMAL' named entity 'RESULTS' named entity 'INDUCED' named entity 'PREDICTION' named entity 'DIAGNOSTIC MARKERS' named entity 'PATIENTS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software